SLGL News and Press, Sol-Gel Technologies Ltd. From 03/25/20

NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products fo...

NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products fo...

Sol-Gel Technologies (NASDAQ: SLGL ): FY GAAP EPS of -$1.26 beats by $0.04 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Top-line generic product revenue of $22.8 million in fiscal 2019 New Drug Applications for Epsolay ® and Twyneo ® remain on track for the second quarter and second half 2020, respectively NESS ZIONA, Israel, March 24, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd...

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences indus...

NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products fo...

The following slide deck was published by Sol-Gel Technologies Ltd. in conjunction with this Read more ...

NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, ...

Gainers : BioXcel Therapeutics (NASDAQ: BTAI )  +58% . More news on: BioXcel Therapeutics, Inc., Genprex, Inc., ImmunoGen, Inc., Stocks on the move, , Read more ...

Thinly traded Sol-Gel Technologies (NASDAQ: SLGL ) slumps  23%  premarket on light volume in response to its public offering of ~2.1M ordinary shares and three-year warrants to purchase up to an aggregate of ~1.7M ordinary shares at a combined price of $11.00 per share and accomp...